雷速体育在8月15日的新闻报道中，奥斯汀·里弗斯在《Ringer NBA》播客中发表了引人注目的观点。他明确表示，如果迈克尔·乔丹没有选择中途退役，那么NBA历史上的得分王将非乔丹莫属，而非现今的詹姆斯。

里弗斯详细解释道，凯文并不像是一个以得分为主要职责的球员。相较之下，迈克尔·乔丹和科比这样的球员才是真正的得分手。他指出，如果乔丹没有在职业生涯中为了追求其他运动如棒球而选择休息两年或一年，并且没有过早退役，那么他的得分能力将会持续攀升。乔丹在40岁时，即便在奇才队回归后，仍然能够场均得到25分的高分，但最终还是选择了再次退役。

里弗斯进一步强调说：“如果乔丹从未因任何原因休息过，并且一直保持着高水平的竞技状态，那么他无疑将成为NBA历史上的得分王。这一点几乎没有任何争议。”

回顾乔丹的职业生涯，他在常规赛中的总得分达到了32292分，排名历史得分榜第五位。而目前詹姆斯则以更为惊人的42184分的总得分排名NBA历史得分榜首位。尽管如此，里弗斯的观点仍让人对历史的走向充满想象和讨论的余地。JPL: Procedures to assess and approve clinical data packages (CDP) in China - Update 2023. How are CDP evaluated in China?

China's medical device and pharmaceutical industry are evolving rapidly, with new technologies and more complex products coming into the market. To ensure that these products are safe and effective, clinical data packages (CDP) need to be properly assessed and approved. In China, a rigorous evaluation process is used to assess CDP. This process involves multiple steps, including the review of clinical data, technical evaluation, and approval by relevant authorities.

In the initial stage of the evaluation process, the clinical data in the CDP are reviewed. This review focuses on the quality, integrity, and completeness of the data. If any issues are found in the data, they are addressed and resolved before proceeding to the next stage. The review may also involve the comparison of the clinical data with international standards or guidelines to ensure that they meet global quality standards.

Next is the technical evaluation stage. This stage involves a more detailed analysis of the clinical data to assess their scientific validity and reliability. This analysis may include evaluating the methods used to collect the data, the sample size, and whether the data support the conclusions drawn from the study. The technical evaluation may also involve considering any safety issues that may arise from using the product.

Finally, the CDP is submitted to relevant authorities for approval. These authorities review the clinical data package to ensure that it meets all regulatory requirements and is consistent with international standards. If any further issues are identified during this review, they are addressed and resolved before final approval is granted.

Once the CDP is approved, it can be used as evidence for product registration and marketing authorization in China. The approval process ensures that only safe and effective products are allowed to enter the market, protecting consumers from potential harm.

What is the role of relevant authorities in this process? What are some challenges faced by companies during this process? How can companies ensure that their CDP is approved?

The role of relevant authorities in the evaluation and approval process of clinical data packages (CDP) in China is crucial. They play a pivotal part in ensuring that all regulatory requirements are met and that the CDP conforms to international standards.

The authorities' responsibilities include reviewing the clinical data package to assess its quality, integrity, and completeness. They also evaluate the scientific validity and reliability of the data, considering factors such as the methods used to collect the data, sample size, and whether the data support the study conclusions. Additionally, they consider any potential safety issues that may arise from using the product.

Some challenges faced by companies during this process include:

1. Compliance with regulations: Companies must ensure that their CDP complies with all regulatory requirements in China. This can be a complex task, as regulations may vary and require a deep understanding of local laws and guidelines.

2. Quality of data: The quality of clinical data is crucial for approval. Companies must ensure that the data is accurate, reliable, and complete. Any issues with the data can delay the approval process or even result in rejection.

3. Technical expertise: The technical evaluation stage requires a high level of technical expertise. Companies may need to engage experienced professionals to help them navigate this complex process.

4. Cost and time: The evaluation and approval process can be costly and time-consuming. Companies must invest resources to ensure that their CDP is properly evaluated and approved.

To ensure that their CDP is approved, companies can take the